A Phase 2, Open-Label, Single-Arm Study of Single-Dose Lead-In and Neoadjuvant Trilaciclib and Chemotherapy in Patients with Early-Stage Triple Negative Breast Cancer (TNBC)

Administered By

Awarded By

Contributors

Start/End

  • March 8, 2022 - March 30, 2027